Dollar Tree names Michael Creedon as chief operating officer
Dollar Tree recently announced that Michael Creedon, Jr. will be joining the organization as chief operating officer.
“I am extremely pleased to announce that Mike Creedon will be joining the Dollar Tree team as our new chief operating officer,” said Mike Witynski, president and CEO. “Mike’s impressive career in retail is rooted in a deep knowledge and understanding of his customers. Mike will be instrumental in driving the execution of our strategy, and a key leader supporting our culture transformation in Dollar Tree, Family Dollar and Dollar Tree Canada stores.”
“I look forward to joining the Dollar Tree organization at this key stage in its transformation,” Creedon said. “We will be committed to improving the in-store experience for our shoppers, as Dollar Tree and Family Dollar are well-positioned to be a critical solve for the millions of households dealing with historic inflation.”
“With Mike Creedon’s arrival and our recent appointments of Jeff Davis, Bobby Aflatooni, Larry Gatta and John Flanigan, we are truly building a world-class retail leadership team that will help to accelerate the growth of the company. In the coming months, I will continue to fill key roles and announce new executive team members. We have a bright future and it is an exciting time to be part of Dollar Tree!” added Witynski.
Dollar Tree operates 16,231 stores across 48 states and five Canadian provinces as of July 30, 2022. Stores operate under the brands of Dollar Tree, Family Dollar and Dollar Tree Canada.
GSK selects Burberry’s Julie Brown as its first female CFO
GSK has appointed its first female CFO, Julie Brown, to succeed Iain Mackay.
Brown’s appointment creates all-female top management at a blue-chip British company and a global pharma major.
Brown, who has extensive experience in the health and pharmaceutical industry, will join GSK from luxury fashion brand Burberry in April and take up the job in May.
Mackay will retire next year after almost four years as GSK's finance chief. His retirement comes after GSK’s spin-off of its large consumer health business, Haleon, in July. It also follows the departure of chief scientific officer Hal Barron in August.
"Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector,” Walmsley said. “We also share a strong passion for people development, diversity, inclusion and sustainability."
Mallinckrodt announces the appointment of Lisa French as chief commercial officer
Specialty pharmaceutical company Mallinckrodt has appointed Lisa French as executive vice president and chief commercial officer, effective Oct. 1, 2022.
French brings more than 30 years of commercial biopharmaceutical experience and will oversee the development and execution of Mallinckrodt's commercialization strategy, the company said. She will serve on the Executive Committee and succeeds Hugh O'Neill, who departed Mallinckrodt as of Sept. 16, 2022.
French most recently built and led the U.S. Women's Health Commercial team for Organon & Co. following its spin-off from Merck. Previously, she held numerous leadership positions at Merck, where she ultimately led all aspects of the brand, executed commercial innovation initiatives and oversaw multiple sales teams.
"I am delighted to welcome Lisa to Mallinckrodt as our new chief commercial officer and a member of our Executive Committee,” said Siggi Olafsson, president and chief executive officer. “Lisa brings decades of commercialization experience, with deep expertise and a proven track record developing and implementing effective and growth-oriented commercialization strategies. I am confident her insights and experience will be invaluable as we continue working to advance our branded pipeline, bring Mallinckrodt's existing products to new markets and geographies and stabilize our portfolio — all for the benefit of our patients, shareholders and other stakeholders."
French said, "One of the reasons I was drawn to Mallinckrodt is the company's focus on innovative drugs, development and commercialization for underserved patients with severe and critical conditions. The company's portfolio benefits from core products with established track records and strong brand recognition. I look forward to working closely with Siggi and the Mallinckrodt team to build on this strong foundation."